Vitality Watch

⚠ Evidence note: Human outcome data on longevity interventions is limited; most claims rest on surrogate markers or animal models. Nothing here is medical advice.

Mentioned 130× · first seen 08-sep-2026 · last seen 16-nov-2026

GLP-1 Receptor Agonists

Current understanding

Semaglutide-class drugs; mortality and inflammation signals are pulling them into the longevity conversation.

Evidence log

Open questions

Related

Contributing findings

pubmed meta analysis human-observational
Weight, Fat Mass, and Lean Mass Changes After Bariatric Surgery and GLP-1-Based Therapy: A Systematic Review and Meta-Analysis.
13-nov-2026 novelty 3 per-area 3 strengthens
press news report anecdotal-biohack
Could microdosing GLP-1 drugs boost longevity?
12-nov-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Will sarcopenia preventative pharmacology ensure the long-term success of GLP-1-derived therapies?
12-nov-2026 novelty 3 per-area 3 strengthens
press news report
Why We May Soon Add ‘Anti-Aging’ to GLP-1s’ Growing Benefits
11-nov-2026 novelty 2 per-area 2 mentions
pubmed trial early human-rct
Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial.
11-nov-2026 novelty 4 per-area 4 strengthens
pubmed review expert-opinion
Nutrition Care Strategies at the Intersection of Menopause and Obesity Pharmacotherapy.
10-nov-2026 novelty 3 per-area 3 strengthens
pubmed review
GLP-1-Based Therapies Across the Menopausal Transition: Dermatologic Considerations and Practical Management.
10-nov-2026 novelty 2 per-area 2 mentions
clinicaltrials trial early expert-opinion
Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes
09-nov-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Weaker or Just Lighter? Monitoring Strength and Function, Not Just Lean Mass, During GLP-1 Weight Loss.
08-nov-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Obesity pharmacotherapies and cognition.
05-nov-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
GLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubes.
04-nov-2026 novelty 3 per-area 3 strengthens
pubmed review
Tirzepatide for the treatment of obstructive sleep apnea: from apnea-hypopnea index reduction to cardiometabolic risk mitigation-a narrative review.
04-nov-2026 novelty 2 per-area 2 strengthens
pubmed observational human-observational
Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness.
01-nov-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Comparative Effects of GLP-1 Receptor Agonists and DPP-4 Inhibitors on Sepsis in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.
30-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational
Glucagon-Like Peptide-1 Receptor Agonists in Obese Heart Failure With Preserved Ejection Fraction.
30-oct-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing.
29-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
GLP-1 Receptor Agonists Decrease the Rate of Rupture, Cardiac Events, and Death in Patients with Abdominal Aortic Aneurysms.
29-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Normal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.
28-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
The use of glucagon-like peptide-1 agonists as a treatment for obesity in older people: risks and benefits.
27-oct-2026 novelty 2 per-area 2 strengthens
pubmed meta analysis human-rct
Cardiovascular Effects of GLP-1 Receptor Agonists Across Age Groups: An Updated Meta-Analysis of Randomized Controlled Trials.
27-oct-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.
26-oct-2026 novelty 3 per-area 3 strengthens
pubmed meta analysis
Effect of glucagon-like-peptide-1 receptor agonists on major cardiovascular outcomes: a systematic review and meta-analysis.
26-oct-2026 novelty 2 per-area 2 strengthens
pubmed observational human-observational
Sustained Versus Minimal GLP-1 Receptor Agonist Exposure and Metabolic Outcomes in Older Adults Without Diabetes.
22-oct-2026 novelty 3 per-area 3 strengthens
pubmed other
Correction: Bone mineral density and turnover response to GLP-1 receptor agonists in older adults with overweight/obesity and prediabetes/type 2 diabetes: a 20-week pilot trialanalysis.
19-oct-2026 novelty 1 per-area 1 mentions
pubmed review
GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes.
18-oct-2026 novelty 2 per-area 2 strengthens
pubmed review
Glucose-Lowering Therapies in Type 2 Diabetes-Associated Sarcopenia: Mechanisms, Clinical Evidence and a Muscle-Centred Framework.
17-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
GLP-1 receptor agonist treatment and cardiovascular outcomes following aortic valve replacement: a nationwide observational study.
16-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational
Changes in Gait Speed During a 12-Month Multidisciplinary Obesity Management Program Including Semaglutide: A Real-World Observational Study in Japanese Adults With Musculoskeletal Disorders.
15-oct-2026 novelty 2 per-area 2 strengthens
pubmed review expert-opinion
"Ozempic Face" and Facial Aging.
10-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Tirzepatide versus other glucose-lowering therapies and risk of COPD exacerbations in patients with comorbid type 2 diabetes: a retrospective cohort study.
09-oct-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP-1-Based Therapy.
07-oct-2026 novelty 3 per-area 3 strengthens
clinicaltrials observational
GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes
05-oct-2026 novelty 2 per-area 2 mentions
pubmed review expert-opinion
Bidirectional Pharmacology of GIP Receptor Targeting in Obesity: Historical Foundations, Mechanistic Divergence, and Translational Boundaries.
05-oct-2026 novelty 3 per-area 3 strengthens
pubmed review expert-opinion
Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics.
02-oct-2026 novelty 3 per-area 3 strengthens
pubmed news report expert-opinion
Semaglutide Demonstrates Benefits Across Frailty Levels.
02-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Are we at risk of increasing sarcopenia? Implications for osteoarthritis and osteoporosis.
02-oct-2026 novelty 2 per-area 3 weakens
pubmed observational human-observational
Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program.
01-oct-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Tirzepatide and the prevention of heart failure in obesity: a multi-center cohort study using the TriNetX database.
01-oct-2026 novelty 3 per-area 3 strengthens
pubmed trial late human-rct
Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
01-oct-2026 novelty 3 per-area 3 strengthens
pubmed review
Semaglutide in type 2 diabetes and chronic kidney disease in Australia: practical clinical considerations from a multidisciplinary panel.
30-sep-2026 novelty 2 per-area 2 strengthens
pubmed review expert-opinion
Beyond Skin Laxity: GLP-1 Receptor Agonist-Induced Lean Mass Depletion and Surgical Tissue Quality in Aesthetic Surgery: A Narrative Review.
29-sep-2026 novelty 3 per-area 3 strengthens
pubmed observational
Comparative outcomes of GLP-1 receptor agonist and SGLT2 inhibitor users after liver transplantation: An emulated target trial.
29-sep-2026 novelty 2 per-area 2 strengthens
pubmed meta analysis
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes.
28-sep-2026 novelty 2 per-area 2 strengthens
pubmed review
Beyond weight loss: a narrative review of tirzepatide's impact on muscle and lean mass in people with overweight and obesity.
28-sep-2026 novelty 2 per-area 2 strengthens
pubmed review expert-opinion
Losing Muscle or Restoring Physiology? Reframing the Incretin Therapy Sarcopenia Concern.
28-sep-2026 novelty 3 per-area 3 strengthens
pubmed preclinical mechanism-plausible
Discovery of Fisetin as a potent and cell-active ACVR2A inhibitor.
27-sep-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
27-sep-2026 novelty 3 per-area 3 strengthens
pubmed meta analysis human-rct
GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks.
26-sep-2026 novelty 3 per-area 3 strengthens
pubmed observational human-observational
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity.
26-sep-2026 novelty 3 per-area 3 strengthens
pubmed preclinical animal-model
An RNA thermogenic therapy to preserve lean mass and enhance metabolic health during GLP-1 weight loss.
25-sep-2026 novelty 4 per-area 4 strengthens

build build 880 · 2bcef25 · 2026-11-18